Pristanic acid
Based on 1 Customer Validation
Pristanic acid is an endogenous metabolite present in Blood that can be used for the research of Alpha Methylacyl CoA Racemase Deficiency and Zellweger Syndrome.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.94%
- No. CAS: 1189-37-3
- Fòrmula: C19H38O2
- Peso molecular:298.50
-
Almacenamiento:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Lipid Compound Library
HY-L043
-
Food-Sourced Compound Library
HY-L094
-
Human Metabolite Library
HY-L123
-
Animal-Sourced Natural Product Library
HY-L157
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Bioactive Compound Library
HY-L001
-
Fatty Acids Compound Library
HY-L182
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Endogenous Metabolite Library
HY-L207
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
Human Endogenous Metabolite Compound Library
HY-L030
Ver todos los productos específicos de isoformas Endogenous Metabolite
More
Actividad biológica
|
Human Endogenous Metabolite |
Endogenous metabolites is defined as those that are annotated by Kyoto Encyclopedia of Genes and Genomes as substrates or products of the ~1900 metabolic enzymes encoded in our genome. It is clear in the body of literature that there are documented toxic properties for many of these metabolites[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 1189-37-3
-
Appearance Liquid (Density: 0.882±0.06 g/cm3)
-
Peso molecular 298.50
-
Fòrmula C19H38O2
-
Color Colorless to light yellow
-
SMILES
CC(C)CCCC(C)CCCC(C)CCCC(C)C(O)=O
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : 50 mg/mL (167.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (267 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720. [Content Brief]
[2]. McLean BN, et al. A new defect of peroxisomal function involving pristanic acid: a case report. J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):396-9. [Content Brief]
[3]. Baumgartner MR, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol. 1998 Nov;44(5):720-30. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3501 mL | 16.7504 mL | 33.5008 mL | 83.7521 mL |
| 5 mM | 0.6700 mL | 3.3501 mL | 6.7002 mL | 16.7504 mL | |
| 10 mM | 0.3350 mL | 1.6750 mL | 3.3501 mL | 8.3752 mL | |
| 15 mM | 0.2233 mL | 1.1167 mL | 2.2334 mL | 5.5835 mL | |
| 20 mM | 0.1675 mL | 0.8375 mL | 1.6750 mL | 4.1876 mL | |
| 25 mM | 0.1340 mL | 0.6700 mL | 1.3400 mL | 3.3501 mL | |
| 30 mM | 0.1117 mL | 0.5583 mL | 1.1167 mL | 2.7917 mL | |
| 40 mM | 0.0838 mL | 0.4188 mL | 0.8375 mL | 2.0938 mL | |
| 50 mM | 0.0670 mL | 0.3350 mL | 0.6700 mL | 1.6750 mL | |
| 60 mM | 0.0558 mL | 0.2792 mL | 0.5583 mL | 1.3959 mL | |
| 80 mM | 0.0419 mL | 0.2094 mL | 0.4188 mL | 1.0469 mL | |
| 100 mM | 0.0335 mL | 0.1675 mL | 0.3350 mL | 0.8375 mL |
Pristanic acid Related Classifications
HY-113024 Related Classifications
Powered by Bioz